Anti-cytokine therapy for psoriasis - not only TNF-α blockers. Overview of reports on the effectiveness of therapy with IL-12/IL-23 and T and B lymphocyte inhibitors

TNF-alpha inhibitors - infliximab, etanercept and adalimumab - can be used in the treatment of psoriasis vulgaris and psoriatic arthritis, along with other inhibitors of proinflammatory cytokines, such as interleukin-12 (IL-12) and IL-23. This paper presents the results of research on the use of biological drugs other than the tumor necrosis factor blockers (TNF-alpha), namely inhibitors of IL-12 and IL-23 (ustekinumab), T-cell inhibitors (alefacept and efalizumab), B-cell inhibitors (rituximab), anti-IL-17 agents (secukinumab, ixekizumab, and brodalumab) and IL23p19 inhibitors (guselkumab and tildrakizumab). The paper presents an analysis of the mechanism of action, recommended doses and methods of therapy, taking into account the adverse events associated with the use of anti-cytokine therapy. The use of biological drugs is discussed based on a review of the current literature.